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a b s t r a c t
Improving outcomes among class 3 thalassemia patients receiving allogeneic hematopoietic stem cell trans-
plantations (HSCT) remains a challenge. Before HSCT, patients whowere 7 years old and had a liver size 5 cm
constitute what the Center for International Blood and Marrow Transplant Research deﬁned as a very higherisk
subset of a conventional high-risk class 3 group (here referred to as class 3 HR).We performedHSCT in 98 patients
with related and unrelated donor stem cells. Seventy-six of the patients with age < 10 years received the more
conventional myeloablative conditioning (MAC) regimen (cyclophosphamide, busulfan,  ﬂudarabine); the
remaining 22 patients with age  10 years and hepatomegaly (class 3 HR), and in several instances additional
comorbidity problems, underwent HSCT with a novel reduced-toxicity conditioning (RTC) regimen (ﬂudarabine
and busulfan). We then compared the outcomes between these 2 groups (MAC versus RTC). Event-free survival
(86% versus 90%) and overall survival (95% versus 90%) were not signiﬁcantly different between the respective
groups; however, there was a higher incidence of serious treatment-related complications in the MAC group, and
althoughwe experienced 6 graft failures in theMAC group (8%), therewere none in the RTC group. Based on these
results,we suggest that (1) class 3HR thalassemia patients can safely receiveHSCTwith our novel RTC regimenand
achieve the same excellent outcome as low/standard-risk thalassemia patients who received the standard MAC
regimen, and further, (2) that thisnovelRTCapproach shouldbe tested in the low/standard-riskpatientpopulation.
 2014 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative treatment for thalassemia
patients [1]. A myeloablative conditioning regimen (MAC) of
busulfan (Bu) followed by 4 days of cyclophosphamide (Cy)
(BuCy4) has, for several years, been considered the standard
of care for HSCT in severe thalassemias [2]. The outcome of
HSCT is dependent on patients’ pretransplantation risk
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factors, which are related to the degree of underlying organ
damage, mostly commonly in the form of complications of
chronic blood transfusions [3]. The currently used risk
stratiﬁcation for severe thalassemia patients undergoing
MAC HSCT has signiﬁcant limitations; it fails to recognize a
very higherisk subgroup, consisting of patients who are  7
years old and who have hepatomegaly (liver size extending
 5 cm below the costal margin). Such patients constitute
what Mathews et al. and the Center for International Blood
and Marrow Transplant Research have deﬁned as a very
higherisk subset of a conventional high-risk (HR) class 3
group [4,5]. This subset is characterized by a very high risk of
graft rejection and regimen-related toxicity, including, but
not limited to veno-occlusive disease (VOD)/sinusoidal
obstruction syndrome, often leading to multiorgan failure
and death [4,5]. This stimulated the design and evaluation of
a number of different pretransplantation conditioning regi-
mens for this group [3,6-11].
Thalassemia patients often have a long history of frequent
blood transfusions as part of their medical management his-
tory. Therefore, they also have an excessive risk for graft fail-
ure and regimen-related toxicity/mortality. We now
hypothesized that patients with hemoglobinopathies, here
exempliﬁed by thalassemia, who have a normal, if not hy-
peractive immune system, need to be preconditioned in a
more comprehensive way than is typically done for other
patients. The far-reaching treatment program would encom-
pass 3 distinct phases. The ﬁrst part would be one of medical
management, and consists of oral hydroxyurea to reduce
erythroid marrow expansion, together with chelation therapy
to reduce (hepatic) iron deposits, thereby decreasing the risk
for hepatic toxicity of the conditioning regimen. The second
phasewould involve the added immunosuppressive beneﬁt of
2 courses of timed, sequential pharmacological therapy that
are added without imposing signiﬁcant toxicity on the third
phase, the conditioning program itself, which consists of a
reduced-toxicity conditioning (RTC) regimen of ﬂudarabine
(Flu) with Bu and antithymocyte globulin (ATG), as previously
spear-headed by Russell et al. and de Lima et al. for hemato-
logical malignancies, and which has proven itself to be both
medically safe and fraught with an extremely low risk for graft
failures in patients who receive both matched related and
unrelated donor grafts [12,13]. Finally, when procuring the
graft itself, we would routinely strive for securing as many
cells as possible to minimize the risk for graft failure.
We recently introduced this new comprehensive concept
of pretransplantation pharmacological immunosuppression
therapy followed by Flu and Bu as a composite conditioning
platform for class 3HR thalassemiapatients [14]. In the current
investigation, we compared the outcomes of an expanded
cohort of older (class 3HR) patients undergoingHSCTwith our
novel approach (expanded from 13)with that of younger class
3 patients who received a standard MAC (BuCy4-based)
regimen. To our knowledge, no onehas hitherto comparatively
analyzed the outcome of severe thalassemia patients who
underwent transplantation with these risk-stratiﬁed condi-
tioning approaches. Based on the very favorable outcome in
this highest-risk subpopulation, we suggest that this modiﬁed
RTC program should be considered for more widespread
testing also in low/standard-risk patients.
PATIENTS AND METHODS
One hundred and twenty consecutive thalassemia patients underwent
HSCT at the Ramathibodi Hospital between 1989 and 2013. In the current
comparison, we excluded 7 patients who received cord blood stem cells, 8
patients who received a different RTC regimen [15] and, more recently, 7
patients who have been treated on a haploidentical donor transplantation
program. Therefore, 98 patients were included. Sixty-ﬁve of these 98 pa-
tients received related and 33 patients received unrelated donor grafts. The
data concerning some of these 98 patients were previously reported
[14,16,17]. Patients and donors or their parents/caregivers signed informed
consent before treatment. We stratiﬁed patients to receive MAC or RTC
regimens depending on age and hepatomegaly ( 5 cm below right costal
margin). The patients who were older than 10 years and had hepatomegaly
received the RTC regimen; all were classiﬁed as class 3 according to the
criteria proposed by Lucareilli et al. [1]. This group of patients is also strat-
iﬁed as class 3 HR as described previously [4,5]. Among the 22 patients who
received the RTC regimen, 2 had rejected a previous HSCTand 1 had rejected
2 previous HSCTs. In addition, several of these 22 patients also had serious
comorbidities; 2 had diabetes mellitus type 1, 1 had extensive extra-
medullary hematopoiesis, 2 patients had a history of pulmonary hyper-
tension, and 7 had previously undergone splenectomy [18].
Histocompatibility
HLA was determined by conventional serologic typing or DNA typing
with intermediate- or high-resolution sequence-speciﬁc oligonucleotide
probes for class I and II loci.
Conditioning Regimens
MAC regimen
The MAC regimen [16,17] consisted of Bu 1 mg/kg taken orally or .95 to
1.2 mg/kg i.v. every 6 hours for 4 days (day -9 to day -6) and cyclophos-
phamide 50 mg/kg infused daily for 4 days (day -5 to day -2) in patients who
received matched related donor stem cells (BuCy4). Because of the risk of
graft failure, the patients who received unrelated and mismatched related
donor stem cells had the BuCy4 regimenmodiﬁed as follows: Flu 30 mg/m2/
day i.v. was given once daily for 6 days (day -15 to day -10), Bu (the same
dose as previously mentioned) for 4 days (day -15 to day -12), Cy 50 mg/kg
for 4 days (day -9 to day -6), and antilymphocyte globulin (Fresenius,
Graefelﬁng, Germany) 10 mg/kg/day was infused daily for 4 days (day -5 to
day -2).
RTC regimen, Group 3 HR patients
Pretransplantation management was utilized for all patients who
received the RTC regimen [14]. Before starting the immunosuppressive
phase, all patients received hydroxyurea 20 mg/kg/day daily  3 months to
decrease erythroid marrow expansion [14,15]. The RTC regimen consisted of
2 phases.
The ﬁrst phase was sequential pharmacological pretransplantation
immunosuppression (PTIS). The ﬁrst 11 patients received 1 cycle; subse-
quently, we used 2 cycles of PTIS consisting of Flu 40 mg/m2/day i.v. for 5
days and dexamethasone (Dex) 25 mg/m2/day i.v. for 5 days. This treatment
was administered on days -28 to -24 (1 cycle) and subsequently on days -56
to -52 and days -28 to -24 (2 cycles) before transplantation. PTIS is given to
suppress recipient Tcell and facilitate sustainable engraftment. Two patients
in the ﬁrst 11-patient group, who received only 1 cycle of Flu-Dex, had
unstable donor chimerism in the ﬁrst 100 days after HSCT. Because there
was no clinical toxicity from the Flu-Dex, we administered 2 cycles, 28 days
apart, in the next 11 patients.
The second phase was the conditioning regimen, which consisted of Flu
35 mg/m2/day i.v. for 6 days (day -10 to day -5) followed by Bu 130 mg/m2
i.v. once daily for 4 days (day -10 to day -7) and ATG (Thymoglobulin;
Sanoﬁ-Genzyme Canada, Ontario, Canada) 1.5 mg/kg/day for 3 days (day -4
to day -2).
Stem Cell Grafts
The T cell replete bone marrow or peripheral blood stem cell graft was
infused on day 0. For patients undergoing RTC, peripheral blood stem cells
were collected to target 5-10  106 CD34þ cells/kg recipient weights.
Graft-versus-host Disease Prophylaxis
For graft-versus-host disease (GVHD) prophylaxis, all patients started
cyclosporin or tacrolimus 2 to 4 days before transplantation. In addition, all
MAC patients received a short course of methotrexate, whereas the patients
in the RTC group received mycophenolate mefotil for 60 days.
VOD Prevention and Treatment
Because the patients in RTC group are at high risk of VOD, we therefore
monitored weight, ﬂuid balance, and liver function tests closely. For the
treatment of VOD, we usually gave supportive care including analgesia,
diuretics, and packed red cell transfusion to keep hematocrit > 30. We also
tried to minimize nephrotoxins and hepatotoxins.
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Statistics
Survival probability was estimated by the Kaplan-Meier method.
RESULTS
The 5-year event-free and overall survival for all 98 pa-
tients were 87% (95% conﬁdence interval [CI], 76.6% to 91.1%)
and 94% (95% CI, 86.3% to 97.1%), respectively. The 5-year
event-free survival estimated for recipients in the related-
donor group was 88% (95% CI, 76.4% to 93.5%) compared
with 82% (95% CI, 63.2% to 91.2%) in the unrelated-donor
group respectively (P ¼ .46) (Figure 1A). The 5-year overall
survival rate estimated for recipients in the related-donor
group was 94% (95% CI, 84.1% to 97.6%) compared with 94%
(95% CI, 76.4% to 98.3%) in the unrelated-donor group
(P ¼ .96) (Figure 1B).
MAC versus RTC Groups
Seventy-six patients were assigned to receive the MAC
regimen and 22 patients were allocated to the RTC regimen.
This is based on a new risk stratiﬁcation described previously
[4,5]. The patient characteristics of the 2 risk groups are
described in Table 1. The event-free survival estimated for
recipients in MAC and RTC groups was 86% (95% CI, 73.8% to
90.7%) and 90% (95% CI, 64.8% to 97.3%), respectively (P ¼ .5)
Figure 1. (A). Event free survival of 98 thalassemia patients undergoing related and unrelated donor HSCT (related: n ¼ 65; unrelated: n ¼ 33). (B) Overall survival of
98 thalassemia patients undergoing related and unrelated donor HSCT (related: n ¼ 65; unrelated: n ¼ 33).
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and the overall survival was 95% (95% CI, 86.4% to 98.0%) and
90% (95% CI, 64.7% to 97.3%), respectively (P ¼ .9)
(Figure 2A,B). The thalassemia-free survival estimated for
recipients in MAC and RTC was 88% (95% CI, 75.2% to 91.5%)
and 93% (95% CI, 66.2% to 98.2%), respectively (P¼ .50). In the
MAC group, 6 of 76 patients (8%) had graft rejection. In
contrast, none in the RTC patient group had graft rejection
(P ¼ .10). At the time of report, all patients in both groups
who are free of thalassemia have full donor chimerism,
except 1 patient in MAC group who has stable mixed
chimerism (80% donor chimerism) 7 years after HSCT.
Severe grade III and IV acute GVHD and extensive stage
chronic GVHD occurred equally between the MAC and RTC
groups (Table 1).
DISCUSSION
Improving the clinical outcome of class 3 HR thalassemia
after an allogeneic HSCT remains a challenge. Mathews et al.
and the Center for International Blood and Marrow Trans-
plant Research [4,5] previously reported on the poor
outcome of patients in a newly deﬁned class 3 HR subset
after HSCT when using BuCy4. The major contributory factor
for the poor outcome in these patients was the combination
of a high risk for graft rejection and serious regimen-related
toxicity/treatment-related mortality (TRM). Earlier attempts
to reduce regimen-related toxicity in a similar cohort of pa-
tients were made by reducing the cumulative of doses of Bu
and Cy. Experience from such an approach, as reported by
the Pesaro group, suggested that although reduction of TRM
was achieved, there was a signiﬁcantly higher risk of graft
rejection [8]. Although other investigators have reported an
improvement in outcome of class 3 patients after HSCT, we
would carefully argue that most, if not all, of such published
data refer to class 3 patients in general, but they do not
address the very higherisk subset of class 3 (class 3HR) that
was deﬁned by Mathews et al. and Sabloff et al. [4,5].
It is noteworthy that although 6 of 76 patients (8%) in our
MAC group suffered graft failure, our second cohort of 22
class 3 HR patients undergoing our new approach with PTIS
followed by a BuFlu-based RTC regimen demonstrated that
all patients can achieve stable full donor chimerism [14 and
current report]. We suggest that our new PTIS RTC approach
is of particular beneﬁt for these class 3 HR patients, who are
now offered the chance to safely achieve full engraftment
without thalassemia in exchange for a more limited risk of
serious treatment-related toxicity. However, the risk of
serious toxicity and (still) a relatively high graft failure point
out that this methodology may be of additional beneﬁt to
other class 3 patients as well.
Six patients in theMAC group had graft rejection. Three of
these 6 patients received unrelated and the other 3 patients
received related-donor stem cells. For the unrelated patients,
2 received 2 allele mismatched stem cells (6/8 HLA alle-
leematched donor) and 1 received bone marrow stem cells
with the dose of CD34þ less than 2  106 cells/kg. For the
related patients, 1 of them received 1 antigenemismatched
stem cells (5/6 HLA matched donor) and 2 received bone
marrow stem cells with the dose of CD34þ less than 2  106
cells/kg. We suggest that disparity of HLA matching and low
CD34þ dose may be the causes of rejection.
Previous studies have reported thalassemia-free survival
rates of 50% to 80% after HSCT in patients with thalassemia
with class 3 HR features, such as older age and hepatomegaly
[4,5,7,9-11]. Mathews et al. has reported using treosulfan, Flu,
and thiotepa for a conditioning regimen in 24 class 3 HR
patients and the result showed that thalassemia-free and
overall survival were 77.8% and 86.6%, respectively [10]. In
this current study, the 22 class 3 HR patients who underwent
PTIS RTC can achieve both event-free and overall survival in
excess of 90%, whereas thalassemia-free survival is around
93% in this group. Wewant to emphasize that, by design, our
study included patients with not only class 3 HR features but
also thosewho had failed a previous HSCT, as well as patients
who suffer comorbidities, such as diabetes mellitus, extra-
medullary/hepatic hematopoiesis, pulmonary hypertension,
and those having undergone a splenectomy, all of which are
recognized as risk factors for TRM; furthermore, 5 of the 22
patients received grafts from mismatched donors. With this
adverse risk information in mind, we suggest that our
approach should be considered promising for use in high-
risk patients who are evaluated for possible HSCT.
There is a trend for increasing overall and event-free
survival rate in the unrelated transplantation group in this
current study compared with the previous study (event-free
and overall survival rates: 71% and 82%, respectively) [17].
This is due to better HLA matching by using high-resolution
DNA typing including HLA A, B, C, and DRB1 in the current
practice, instead of only HLA A, B, and DRB1.
In conclusion, our novel comprehensive management
program addresses all components that contribute to high
risk for both treatment-related death and graft failure
in patients with hemoglobinopathies. The sequential
Table 1
Patient Characteristics
Characteristic MAC Regimen RTC Regimen
No. of patients 76 22
Age at transplantation,
median (range), y
8 (2-10) 17 (10-20)
Male/female 44/32 9/13
Type of thalassemia
Homozygous b thalassemia 17 7
b Thalassemia/hemoglobin E 59 15
Source of stem cells
Bone marrow/peripheral blood 64/12 1/21
HLA matching
Related 50 15
6/6 HLA antigen match 44 13
5/6 HLA antigen match 6 2
Unrelated 26 7
6/6 Allele match 13 -
5/6 Allele match 6 -
4/6 Allele match 2 -
8/8 Allele match 2 4
7/8 Allele match 3 3
GVHD
Acute, grade II-IV 18 (22%) 5 (23%)
Acute, grade III-IV 5 (6%) 3 (13%)
Chronic 8 (10%) 4 (18%)
Extensive 4 (5%) 1 (4%)
Procedure-related complications
Hemorrhagic cystitis 6 (7%) 1 (4%)
Herpes zoster infection 3 (4%) 2 (8%)
Cytomegalovirus infection 2 (2%) 1 (4%)
Sepsis 4 (5%) -
Autoimmune hemolytic anemia 1 (1%) -
Seizure 3 (4%) -
VOD 5 (6%) 2 (8%)
Causes of death 5 (7%) 2 (9%)
Graft failure 1 -
Bleeding 1 -
Viral infections 1 -
Fungal infection 1 1
Accident 1 1
Follow-up, median (range), mo 114 (11.5-262) 36 (5-88)
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administration of hydroxyurea, followed by PTIS and subse-
quently an RTC regimen of Flu, Bu, and ATG, paired with a
relatively high number of hematopoietic progenitor cells (on
average > 5  106 CD34þ cells/kg of recipient weight), has
been demonstrated to result in a high level of safety and
durable engraftment in this group of patients with high-risk
class 3 thalassemia. Based on the very favorable outcome in
this highest-risk subpopulation, we suggest that this modi-
ﬁed RTC program should be considered for more widespread
testing in low and standard-risk patients to further decrease
the risk of toxicity and graft failures among these patients as
well. In addition, the rapid achievement of stable engraft-
ment in the 5 patients who had partially mismatched donors
suggests that this new program could be safely modiﬁed for
use with alternative donors in patients who lack fully
matched donors.
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